Jan 18 | News
Genzyme has announced that the EMA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme(R).
|
Nov 16 2011 | News
Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.
|
Nov 10 2011 | News
Genzyme announced today the appointment of William "Bill" Sibold as Head of Multiple Sclerosis and Rogerio Vivaldi as Head of Rare Diseases. Both will report to David Meeker, President and Chief Executive Officer of Genzyme, and will join the Genzyme Executive Team. The MS and Rare Disease businesses constitute Genzyme's core focus following its integration with Sanofi.
|
Oct 25 2011 | News
Sanofi announced Monday the appointment of current Genzyme COO David Meeker to the role of CEO of Genzyme effective November 1. Meeker will report to Sanofi CEO Christopher A. Viehbacher, who will retain the position of chairman of Genzyme.
|
Sep 2 2011 | News
PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration.
|
Apr 12 2011 | News
CAMBRIDGE,
Mass. (AP) — Aveo Pharmaceuticals
Inc. said today it appointed Henri Termeer, the outgoing chairman, CEO and
president of Genzyme Corp., to the Aveo board of directors.
|
Mar 7 2011 | News
Genzyme Corporation announced today that its Board of
Directors unanimously recommends that Genzyme shareholders accept the
sanofi-aventis revised tender offer to purchase all outstanding shares of
Genzyme common stock for $74.00 and one contingent value right, per share.
|
Mar 1 2011 | News
CAMBRIDGE,
Mass. (AP) —Genzyme Corp. said today
that it completed the sale of its pharmaceutical intermediates business,
finishing a plan announced last year to sell three businesses so it can focus
on core growth areas.
|
Feb 28 2011 | Blogs
The strategic reasons behind the acquisition in the works
for Sanofi to purchase Genzyme are clear. It was a matter of fixing a sale
price that reflected the true current and future value of Genzyme.
|
Feb 1 2011 | News
Genzyme Corporation today announced that it has completed
the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for
$265 million in cash.
|